CDC Guidelines for Use of QuantiFERON®-TB Gold Test

Slides:



Advertisements
Similar presentations
Contact Evaluation Your name Institution/organization Meeting Date International Standards 18, 19.
Advertisements

TB Disease and Latent TB Infection
Purpose of 2005 Guidelines Update and replace 1994 Mycobacterium tuberculosis infection control (IC) guidelines Further reduce threat to health-care workers.
Implementing NICE guidance
VDH TB Control and Prevention Program
TB in Tennessee The Good, the Bad, and the Ugly Jason Cummins, MPH April 30, 2014.
Ebola Facts October 28, /28/14 Identify, Isolate, Inform: ED Evaluation and Management The following diagram provides guidance on evaluation and.
Community-Driven Tuberculosis Interventions for Aboriginal Communities
Tuberculosis in Children: Prevention Module 10C - March 2010.
Page Up to Reverse  Employee Health  Page Down to Advance  Employee Health 
Why do we test? 1.We want to prevent an outbreak of Tuberculosis in our campus community 2.We want to find those that are affected and get them treated.
Latent TB When infected with M Tuberculosis, but do not have active tuberculosis disease. Patients are not infectious. TB infections in Australia are predominantly.
Routine HIV Screening in Health Care Settings David Spach, MD Clinical Director Northwest AIDS Education and Training Center Professor of Medicine, Division.
Tuberculosis Control What’s New. TB Regional Nurse Update Teri Lee Dyke, RN, BSN, CIC Julie McCallum, RN, MPH Regional TB Nurse Consultants.
Staff Health Care Infectious Disease view Jameel Adnan, MD. Community & Primary Health Care KAAU- RABEG BRANCH.
Why do we test? 1.We want to prevent an outbreak of Tuberculosis in our campus community 2.We want to find those that are affected and get them treated.
TB Testing Current Thinking
Latent Tuberculosis among Displaced Populations Rapid Diagnosis and Control Nikolaou Aristidis MD, MSc.
October 3, Serial Testing of Health Care Workers for Tuberculosis Using Interferon-γ Assay Madhukar Pai, et. al. American Journal of Respiratory.
1 Meeting with Contacts for TB Assessment. Learning Objectives After this session, participants will be able to: 1.Explain why contact assessments are.
Current international guidelines recommend 6–9 months of isoniazid (INH) preventive chemotherapy to prevent the development of active tuberculosis in.
Allen Kraut, MD, FRCPC Medical Director, Occupational Health WRHA
Use of Network Analysis During a Tuberculosis Investigation Outbreak Investigation Section Surveillance and Epidemiology Branch Division of Tuberculosis.
IGRAs in Practice: The San Francisco Health Department Experience Jennifer Grinsdale, MPH Program Manager/Epidemiologist Acting Director Tuberculosis Control.
Infection Control: New CDC Guidelines Kevin Fennelly, MD, MPH 2006 Northeast TB Controllers Meeting Relapse? The State of TB Control in the Era of Declining.
Evaluating Tuberculosis Surveillance and Action in an Urban and Rural Setting Kristine Lykens, Ph.D. In collaboration with Anita Kurian, MPH, MBBS Patrick.
Use of 12 weekly doses of isoniazid and rifapentine for the treatment of latent tuberculosis − Connecticut , Kelley Bemis, MPH CDC/CSTE Applied.
Tuberculosis Egan’s Chapter 22. Mosby items and derived items © 2009 by Mosby, Inc., an affiliate of Elsevier Inc. 2 Tuberculosis (TB) The incidence of.
Implementing a Rapid HIV Testing Guideline for L&D NNEPQIN April 30, 2007.
Routine HIV Screening in Health Care Settings David Spach, MD Clinical Director Northwest AIDS Education and Training Center Professor of Medicine, Division.
Module 2 - Epidemiology of Tuberculosis
Screening for TB.
بسم الله الرحمن الرحيم. A 25 year old Saudi male applied to work as paramedic. He has no symptoms or history of contact with sick patients. His physical.
IGRAs: Should they replace the TST in the identification of latent tuberculosis? Objectives Describe how interferon-gamma release assays (IGRAs) work.
CDC Guidelines for Use of QuantiFERON ® -TB Gold Test Philip LoBue, MD Centers for Disease Control and Prevention Division of Tuberculosis Elimination.
Severe Acute Respiratory Syndrome (SARS) and Preparedness for Biological Emergencies 27 April 2004 Jeffrey S. Duchin, M.D. Chief, Communicable Disease.
The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and.
Contact Investigation Dr. Essam Elmoghazy. Contact Investigations – A Crucial Prevention Strategy On average, 10 contacts are identified for each person.
More information © 2015 Denver Public Health Michelle K Haas, Kaylynn Aiona, Pete Dupree, Ellen Brilliant, Robert Belknap Improving access to Tuberculosis.
Investigation of Contacts of Persons with Infectious Tuberculosis, 2005 Division of Tuberculosis Elimination Centers for Disease Control and Prevention.
Severe Acute Respiratory Syndrome (SARS) and Preparedness for Biological Emergencies 27 April 2004 Jeffrey S. Duchin, M.D. Chief, Communicable Disease.
TB Prevention and Control in Correctional and Detention Facilities Mark Lobato, MD Division of TB Elimination Centers for Disease Control and Prevention.
Comparison of a New ESAT-6/ CFP-10 Peptide-Based Gamma Interferon Assay to Tuberculin Skin Test for Tuberculosis Screening in a Moderate Risk Population.
Diagnosis of pulmonary tuberculosis
Universal Opt-Out Screening for HIV in Health Care Settings, Cost Effectiveness in Action Douglas K. Owens, MD, MS VA Palo Alto Health Care System and.
Depart. of Pulmonology 백승숙. More than 80% of cases of tuberculosis in the United States –The result of reactivated latent infection –Nearly all these.
Shingai Machingaidze, Suzanne Verver, Humphrey Mulenga, Deborah-Ann Abrahams, Mark Hatherill, Willem Hanekom, Gregory D. Hussey, and Hassan Mahomed Am.
TB: The Elispot In The Room Dr Jessica Potter TB Research Registrar Barts Health NHS Trust.
TB Disease and Infection
Tuberculosis Screening
Institute for Health Service Research for Healthcare Workers (CVcare)
Tuberculosis prevention
Whole-Genome Sequencing; It’s Not Just For Epis
Tolerability of Isoniazid Preventive Therapy (IPT) in an HIV infected cohort
Figure 1. Paradigm for evaluation of those with latent tuberculosis infection (LTBI) based on risk of infection, risk of progression to tuberculosis, and.
This is an archived document.
Tuberculosis prevention
This is an archived document.
QuantiFERON® Blood Test for the Detection of
Time to update guidelines on screening for latent tuberculosis infection in dermatologic patients being treated with tumor necrosis factor-alfa inhibitors 
Hepatitis C Screening Best Practices Jenitza Serrano-Feliciano M.D
بسم الله الرحمن الرحيم.
Mark Lobato, MD Division of TB Elimination
Tolerability of Isoniazid Preventive therapy Among HIV infected Cohort in Nigeria Folajinmi Oluwasina Strategic Information Unit AIDS Healthcare Foundation,
Diagnosed Food Handlers
Time to update guidelines on screening for latent tuberculosis infection in dermatologic patients being treated with tumor necrosis factor-alfa inhibitors 
Algorithm for TB Testing in Children
Tuberculosis.
Perspectives from Los Angeles County Tuberculosis Control Program
Presentation transcript:

CDC Guidelines for Use of QuantiFERON®-TB Gold Test Philip LoBue, MD Centers for Disease Control and Prevention Division of Tuberculosis Elimination

Outline Where to find guidelines Recommendations for QFT-G use Guidance for follow up of Positive test result Negative test result Indeterminate test result Special situations Contact investigation Serial testing (e.g., occupational) Future research needs

Where Can You Find the Guidelines? Print: Guidelines for Using the QuantiFERON®-TB Gold Test for Detecting Mycobacterium tuberculosis Infection, United States, MMWR, December 16, 2005 / Vol. 54 / No. RR-15, pp. 49-54. Internet: http://www.cdc.gov/nchstp/tb/pubs/mmwrhtml/maj_guide.htm

Recommendations for Use of QFT-G

QFT-G can be used in all circumstances in which the TST is used, including Contact investigations Evaluation of recent immigrants who have had BCG vaccination TB screening of health-care workers and others undergoing serial evaluation for M. tuberculosis infection

QFT-G usually can be used in place of (and usually not in addition to) the TST

Follow up of Positive QFT-G

A positive QFT-G should prompt the same health and medical interventions as a positive TST result No reason exists to follow a positive QFT-G with a TST Persons with a positive QFT-G result should be evaluated for TB disease before LTBI is diagnosed After TB has been excluded, treatment of LTBI should be considered

Follow up of Negative QFT-G

The majority of healthy adults who have negative QFT-G results are unlikely to have M. tuberculosis infection and do not require further evaluation

Cautions and Limitations As with a negative TST result, negative QFT-G results should not be used alone to exclude M. tuberculosis infection in persons with symptoms or signs suggestive of TB disease The performance of QFT-G has not been determined in persons who, because of impaired immune function (e.g., HIV infection), are at increased risk for M. tuberculosis infection progressing to TB disease As with a negative TST result, negative QFT-G results alone might not be sufficient to exclude M. tuberculosis infection in immunocompromised persons Limited published data document the performance of QFT-G in children aged <17 years

Follow up of Indeterminate QFT-G

An indeterminate QFT-G result does not provide useful information regarding the likelihood of M. tuberculosis infection Optimal follow up of persons with indeterminate QFT-G results has not been determined Options are to repeat QFT-G with a new blood sample, administer a TST, or do neither Decision should be based on pre-test likelihood of M. tuberculosis infection

Contact Investigations

For persons with recent contact to an infectious TB patient, negative QFT-G results should be confirmed with a repeat test 8-10 weeks after exposure (end of window period) as is recommended for a negative TST

When “window prophylaxis” has been started for high-risk contacts exposed to an infectious TB patient, a negative QFT-G result at the end of the window period should be interpreted in light of all other clinical and epidemiologic data A full course of LTBI treatment should be considered even with a negative result when the rate of M. tuberculosis transmission to other contacts is high or when a false-negative result is suspected because of an immunocompromising medical condition

Serial Testing (e.g., Healthcare Workers)

In situations with serial testing for M. tuberculosis infection (e. g In situations with serial testing for M. tuberculosis infection (e.g., health-care workers), initial two-step testing (necessary for TST) is not necessary for QFT-G In contrast to TST, there is no boosting with QFT-G

Future Research Needs

More data on performance of QFT-G in special populations (e. g More data on performance of QFT-G in special populations (e.g., children, immunocompromised) Longitudinal studies Subsequent TB disease incidence after LTBI has been either diagnosed or excluded with QFT-G Length of time after infection for QFT-G test result to become positive Changes in QFT-G results with therapy for TB disease and LTBI Economic evaluation and decision analysis comparing QFT-G with TST

Questions?